ArticlePloS one2017
Estimating the disease burden of methicillin-resistant Staphylococcus aureus in Japan: Retrospective database study of Japanese hospitals.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Monitoring methicillin-resistantIJID regions · 2025Article
- Burden of Antimicrobial Resistance in Japan: A Systematic Literature Review and Meta-Analysis.Infectious diseases and therapy · 2024Article
- Whole genome sequencing of methicillin-resistant Staphylococcus aureus clinical isolates from Terengganu, Malaysia, indicates the predominance of the EMRSA-15 (ST22-SCCmec IV) clone.Scientific reports · 2024Article
- Antimicrobial Resistance Patterns of Staphylococcus Aureus Isolated at a General Hospital in Vietnam Between 2014 and 2021.Infection and drug resistance · 2024Article
- Article
- The economic value of personal protective equipment for healthcare workers.PLOS global public health · 2023Article
- Molecular co-localization of multiple drugs in a nanoscopic delivery vehicle for potential synergistic remediation of multi-drug resistant bacteria.Scientific reports · 2022Article
- Fractures within 2 years of an obstetric hospitalization: analysis of nationwide administrative data in Japan.Journal of bone and mineral metabolism · 2022Article
- Clinical Implication of the Relationship between Antimicrobial Resistance and Infection Control Activities in Japanese Hospitals: A Principal Component Analysis-Based Cluster Analysis.Antibiotics (Basel, Switzerland) · 2022Article
- Cost and healthcare utilization of methicillin-resistantAntimicrobial stewardship & healthcare epidemiology : ASHE · 2022Article
- Healthcare resources attributable to methicillin-resistant Staphylococcus aureus orthopedic surgical site infections.Scientific reports · 2020Article
- Code-Sharing in Cost-of-Illness Calculations: An Application to Antibiotic-Resistant Bloodstream Infections.Frontiers in public health · 2020Article
- Incidence of residual bacterial contamination of transvaginal ultrasound probes.Journal of medical ultrasonics (2001) · 2019Article
- Ouabain potentiates the antimicrobial activity of aminoglycosides against Staphylococcus aureus.BMC complementary and alternative medicine · 2019Article
- Treatment procedures and associated medical costs of methicillin-resistantSAGE open medicine · 2019Article
- A live vaccine to Staphylococcus aureus infection.Virulence · 2018Article
- Article
- Review
- Safety, tolerability, and immunogenicity of a novel 4-antigenHuman vaccines & immunotherapeutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe nationwide impact of antimicrobial-resistant infections on healthcare facilities throughout Japan has yet to be examined. This study aimed to estimate the disease burden of methicillin-resistant Staphylococcus aureus (MRSA) infections in Japanese hospitals.
designRetrospective analysis of inpatients comparing outcomes between subjects with and without MRSA infection. DATA SOURCE: A nationwide administrative claims database.
setting1133 acute care hospitals throughout Japan.
participantsAll surgical and non-surgical inpatients who were discharged between April 1, 2014 and March 31, 2015.
main outcome measuresDisease burden was assessed using hospitalization costs, length of stay, and in-hospital mortality. Using a unique method of infection identification, we categorized patients into an anti-MRSA drug group and a control group based on anti-MRSA drug utilization. To estimate the burden of MRSA infections, we calculated the differences in outcome measures between these two groups. The estimates were extrapolated to all 1584 acute care hospitals in Japan that have adopted a prospective payment system.
resultsWe categorized 93 838 patients into the anti-MRSA drug group and 2 181 827 patients into the control group. The mean hospitalization costs, length of stay, and in-hospital mortality of the anti-MRSA drug group were US$33 548, 75.7 days, and 22.9%, respectively; these values were 3.43, 2.95, and 3.66 times that of the control group, respectively. When extrapolated to the 1584 hospitals, the total incremental burden of MRSA was estimated to be US$2 billion (3.41% of total hospitalization costs), 4.34 million days (3.02% of total length of stay), and 14.3 thousand deaths (3.62% of total mortality).
conclusionsThis study quantified the approximate disease burden of MRSA infections in Japan. These findings can inform policymakers on the burden of antimicrobial-resistant infections and support the application of infection prevention programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.